APCDD1 shows high specificity for ventral midbrain dopaminergic progenitors in a cell surface marker benchmarking study.

ingentiumby ingentium

In Parkinson's Disease Literature.

Publication date: Jul 20, 2026

Cell surface markers are important tools for quality control (QC) and enrichment of cellular subtypes, such as the dopaminergic (DA) progenitors used for treatment of Parkinson’s disease (PD). However, the regional specificity of many published surface markers is not fully known. Here, we identified APCDD1 as a surface marker with high regional selectivity for caudal ventral midbrain DA fate, outperforming the specificity of seven other previously published markers in flow cytometry analysis. APCDD1 expression correlated with key markers of caudal ventral midbrain DA fate, and antibody-based sorting for APCDD1 enabled enrichment of DA progenitors and depletion of non-DA populations. In regionally mixed neural populations, APCDD1-high, but not APCDD1-low cells, yielded full motoric amelioration after grafting in a rat model of PD, and the APCDD1-high cells produced a higher proportion of DA neurons co-expressing ventral midbrain markers FOXA2 and LMX1A. Taken together, APCDD1 is a promising tool for improving the QC and enrichment of clinically applied cell products for PD.

Open Access PDF

Concepts Keywords
Apcdd1
Da
Dopaminergic
Enrichment
High
Marker
Markers
Midbrain
Pd
Progenitors
Published
Regional
Specificity
Surface
Ventral

Semantics

Type Source Name
disease MESH Parkinson’s disease
disease MESH Dis
pathway REACTOME Reproduction
disease MESH included
disease MESH movement disorder
drug DRUGBANK Dopamine
disease MESH polyposis coli
disease MESH ers
disease MESH dissociation
drug DRUGBANK Papain
drug DRUGBANK Saquinavir
drug DRUGBANK Aspartame
drug DRUGBANK Amphetamine
drug DRUGBANK Vorinostat
drug DRUGBANK Ethanol
drug DRUGBANK Phosphate ion
drug DRUGBANK Human Serum Albumin
drug DRUGBANK Dimethyl sulfoxide
drug DRUGBANK 3 7 11 15-Tetramethyl-Hexadecan-1-Ol
disease MESH ArC
disease MESH Hsd
drug DRUGBANK Water
drug DRUGBANK Fentanyl
drug DRUGBANK Sucrose
drug DRUGBANK Glycerin
disease MESH PBS
drug DRUGBANK Tromethamine
drug DRUGBANK Edetic Acid
drug DRUGBANK Biotin
drug DRUGBANK Abacavir
disease MESH Image
drug DRUGBANK Calusterone
disease MESH CLS
drug DRUGBANK Resiniferatoxin
drug DRUGBANK Coenzyme M
disease MESH AIC
drug DRUGBANK Flunarizine
disease MESH PCT
drug DRUGBANK Adenosine 5′-phosphosulfate
pathway KEGG Parkinson disease
drug DRUGBANK L-Tyrosine
disease MESH Park
drug DRUGBANK Hydroxyethyl Starch
disease MESH hES
disease MESH iPS
pathway REACTOME Translation
disease MESH PSA
disease MESH star
drug DRUGBANK L-Leucine
drug DRUGBANK Dextroamphetamine
disease MESH Lam
drug DRUGBANK Ascorbic acid
drug DRUGBANK Cyclic Adenosine Monophosphate
drug DRUGBANK Diaminopropanol tetraacetic acid
disease MESH strains
drug DRUGBANK Serine
drug DRUGBANK Zinc
pathway REACTOME Gastrulation
disease MESH glioma
pathway KEGG Glioma

Original Article

(Visited 13 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *